| scholarly article | Q13442814 |
| P356 | DOI | 10.1136/JCP.50.5.361 |
| P953 | full work available at URL | https://jcp.bmj.com/content/50/5/361.full.pdf |
| https://europepmc.org/articles/PMC499934 | ||
| https://europepmc.org/articles/PMC499934?pdf=render | ||
| https://syndication.highwire.org/content/doi/10.1136/jcp.50.5.361 | ||
| P932 | PMC publication ID | 499934 |
| P698 | PubMed publication ID | 9215115 |
| P5875 | ResearchGate publication ID | 14004615 |
| P2093 | author name string | J. A. DiGiuseppe | |
| M. B. Kastan | |||
| P2860 | cites work | Apoptosis in the pathogenesis and treatment of disease | Q28235731 |
| Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells | Q28294137 | ||
| Bcl-2-deficient mice demonstrate fulminant lymphoid apoptosis, polycystic kidneys, and hypopigmented hair | Q28586758 | ||
| p53-dependent apoptosis modulates the cytotoxicity of anticancer agents | Q29615031 | ||
| The Fas death factor | Q29620461 | ||
| Mutations in Fas associated with human lymphoproliferative syndrome and autoimmunity | Q33488225 | ||
| Bcl-2 oncoprotein blocks chemotherapy-induced apoptosis in a human leukemia cell line. | Q34358996 | ||
| Bcl-2 initiates a new category of oncogenes: regulators of cell death | Q35675178 | ||
| Expression of Bcl-2 protein and Fas antigen in non-Hodgkin's lymphomas | Q35833999 | ||
| Structural and signaling requirements for BCR-ABL-mediated transformation and inhibition of apoptosis | Q36555271 | ||
| Autonomous proliferation of leukemic cells in vitro as a determinant of prognosis in adult acute myeloid leukemia | Q36776247 | ||
| Stroma-supported culture in childhood B-lineage acute lymphoblastic leukemia cells predicts treatment outcome | Q37351733 | ||
| The control of hematopoiesis and leukemia: from basic biology to the clinic | Q37603531 | ||
| Tumor necrosis factor ligand superfamily: involvement in the pathology of malignant lymphomas. | Q40544191 | ||
| p53 in hematologic malignancies. | Q40627475 | ||
| Control of programmed cell death in normal and leukemic cells: new implications for therapy. | Q40822157 | ||
| The tumor necrosis factor ligand and receptor families. | Q40990575 | ||
| Control of apoptosis in hematopoiesis and leukemia by cytokines, tumor suppressor and oncogenes. | Q41007175 | ||
| Molecular thanatopsis: a discourse on the BCL2 family and cell death. | Q41025122 | ||
| CD4+ T-cell induction of Fas-mediated apoptosis in Burkitt's lymphoma B cells | Q41175299 | ||
| Bcl-2 expression in chronic lymphocytic leukemia and its correlation with the induction of apoptosis and clinical outcome | Q41223060 | ||
| BCR-ABL does not prevent apoptotic death induced by human natural killer or lymphokine-activated killer cells. | Q41235916 | ||
| Fas receptor (CD95)-mediated apoptosis is induced in leukemic cells entering G1B compartment of the cell cycle | Q41271066 | ||
| Cytotoxic T cells overcome BCR-ABL-mediated resistance to apoptosis. | Q41373345 | ||
| Inhibition of apoptosis by BCR-ABL in chronic myeloid leukemia | Q41474016 | ||
| BCR-ABL maintains resistance of chronic myelogenous leukemia cells to apoptotic cell death. | Q41483630 | ||
| Effect of bcl-2 on Fas antigen-mediated cell death | Q41542115 | ||
| Mutations of the p53 gene in myelodysplastic syndrome (MDS) and MDS-derived leukemia. | Q41548934 | ||
| Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome | Q41743756 | ||
| Haemopoietic colony stimulating factors promote cell survival by suppressing apoptosis | Q41748320 | ||
| p53 expression in myeloid cells of myelodysplastic syndromes. Association with evolution of overt leukemia | Q41848991 | ||
| bcl-2-immunoglobulin transgenic mice demonstrate extended B cell survival and follicular lymphoproliferation | Q41964290 | ||
| Treatment of newly diagnosed acute myelogenous leukemia with granulocyte-macrophage colony-stimulating factor (GM-CSF) before and during continuous-infusion high-dose ara-C + daunorubicin: comparison to patients treated without GM-CSF. | Q44784443 | ||
| Clinical significance of p53 mutations in relapsed T-cell acute lymphoblastic leukemia. | Q46121671 | ||
| Nonhereditary p53 mutations in T-cell acute lymphoblastic leukemia are associated with the relapse phase | Q46407204 | ||
| High incidence of potential p53 inactivation in poor outcome childhood acute lymphoblastic leukemia at diagnosis | Q47630133 | ||
| Drug-induced apoptosis in B-cell chronic lymphocytic leukemia: relationship between p53 gene mutation and bcl-2/bax proteins in drug resistance. | Q52519691 | ||
| Altered oncoprotein expression and apoptosis in myelodysplastic syndrome marrow cells. | Q53449499 | ||
| Frequent p53 gene mutations in blast crisis of chronic myelogenous leukemia, especially in myeloid crisis harboring loss of a chromosome 17p | Q53485749 | ||
| BCR-ABL-mediated inhibition of apoptosis with delay of G2/M transition after DNA damage: a mechanism of resistance to multiple anticancer agents. | Q54166756 | ||
| Dominant interfering Fas gene mutations impair apoptosis in a human autoimmune lymphoproliferative syndrome | Q55670225 | ||
| Prognostic significance of bcl-2 protein expression in aggressive non-Hodgkin's lymphoma. Groupe d'Etude des Lymphomes de l'Adulte (GELA) | Q57219095 | ||
| APO-1-induced apoptosis of leukemia cells from patients with adult T-cell leukemia | Q57384667 | ||
| p53 gene mutations and protein overexpression are associated with aggressive variants of mantle cell lymphomas | Q58110137 | ||
| Progression from lymphoid hyperplasia to high-grade malignant lymphoma in mice transgenic for the t(14;18) | Q59085244 | ||
| p53 mutation is associated with progression in follicular lymphomas | Q70482896 | ||
| p53 mutations are associated with histologic transformation of follicular lymphoma | Q70482961 | ||
| Frequent expression of FAS/APO-1 in Hodgkin's disease and anaplastic large cell lymphomas | Q70789099 | ||
| Clinical relevance of BCL-2 overexpression in childhood acute lymphoblastic leukemia | Q70903389 | ||
| p53 mutations in mantle cell lymphoma are associated with variant cytology and predict a poor prognosis | Q71099778 | ||
| Protection of human myeloid leukemic cells against doxorubicin-induced apoptosis by granulocyte-macrophage colony-stimulating factor and interleukin 3 | Q71107578 | ||
| Granulocyte-macrophage colony-stimulating factor associated with induction treatment of acute myelogenous leukemia: a randomized trial by the European Organization for Research and Treatment of Cancer Leukemia Cooperative Group | Q71197371 | ||
| Apoptosis sensitivity in chronic lymphocytic leukemia is determined by endogenous endonuclease content and relative expression of BCL-2 and BAX | Q71483528 | ||
| Multiparameter flow-cytometric analysis of bcl-2 and Fas expression in normal and neoplastic hematopoiesis | Q71556145 | ||
| Indication of an involvement of interleukin-1 beta converting enzyme-like protease in intramedullary apoptotic cell death in the bone marrow of patients with myelodysplastic syndromes | Q71611771 | ||
| Search for rearrangements and/or allelic loss of the fas/APO-1 gene in 101 human lymphomas | Q71774732 | ||
| High expression of bcl-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy | Q72081677 | ||
| Apoptosis in bone marrow biopsy samples involving stromal and hematopoietic cells in 50 patients with myelodysplastic syndromes | Q72344921 | ||
| Simultaneous assessment of cell kinetics and programmed cell death in bone marrow biopsies of myelodysplastics reveals extensive apoptosis as the probable basis for ineffective hematopoiesis | Q72564531 | ||
| p53 mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies | Q72776851 | ||
| Autonomous growth of blast cells is associated with reduced survival in acute myeloblastic leukemia | Q72851107 | ||
| Hematopoietic cells from mice deficient in wild-type p53 are more resistant to induction of apoptosis by some agents | Q72884547 | ||
| Involvement of Fas-mediated apoptosis in the inhibitory effects of interferon-alpha in chronic myelogenous leukemia | Q73062540 | ||
| Tumor necrosis factor ligand superfamily: involvement in the pathology of malignant lymphomas | Q112780708 | ||
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 361-364 | |
| P577 | publication date | 1997-05-01 | |
| P1433 | published in | Journal of Clinical Pathology | Q6294965 |
| P1476 | title | Apoptosis in haematological malignancies | |
| P478 | volume | 50 |
| Q44634472 | Comparative measurement of spontaneous apoptosis in pediatric acute leukemia by different techniques |
| Q38962369 | Unveiling the paradoxical nature of myelodysplastic syndromes (MDS): why hypercellular marrow strongly favors accelerated apoptosis |
| Q73587280 | [Apoptosis: to be or not to be, that is the question] |
Search more.